Suppr超能文献

MUC1癌蛋白抑制ARF-MDM2-p53通路的激活。

MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.

作者信息

Raina Deepak, Ahmad Rehan, Chen Dongshu, Kumar Shailendra, Kharbanda Surender, Kufe Donald

机构信息

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Cancer Biol Ther. 2008 Dec;7(12):1959-67. doi: 10.4161/cbt.7.12.6956. Epub 2008 Dec 9.

Abstract

The MUC1 oncoprotein interacts with the c-Abl tyrosine kinase and blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. Mutation of the MUC1 cytoplasmic domain at Tyr-60 disrupts the MUC1-c-Abl interaction. The present results demonstrate that the MUC1(Y60F) mutant is a potent inducer of the ARF tumor suppressor. MUC1(Y60F) induces transcription of the ARF locus by a c-Abl-dependent mechanism that promotes CUL-4A-mediated nuclear export of the replication protein Cdc6. The functional significance of these findings is that MUC1(Y60F)-induced ARF expression and thereby inhibition of MDM2 results in the upregulation of p53 and the homeodomain interacting protein kinase 2 (HIPK2) serine/threonine kinase. HIPK2-mediated phosphorylation of p53 on Ser-46 was further associated with a shift from expression of the cell cycle arrest-related p21 gene to the apoptosis-related PUMA gene. We also show that the MUC1(Y60F) mutant functions as dominant negative inhibitor of tumorigenicity. These findings indicate that the oncogenic function of MUC1 is conferred by suppressing activation of the ARF-MDM2-p53 pathway.

摘要

MUC1癌蛋白与c-Abl酪氨酸激酶相互作用,并在对DNA损伤的凋亡反应中阻断c-Abl的核靶向。MUC1胞质结构域的Tyr-60位点发生突变会破坏MUC1与c-Abl的相互作用。目前的结果表明,MUC1(Y60F)突变体是ARF肿瘤抑制因子的有效诱导剂。MUC1(Y60F)通过一种依赖c-Abl的机制诱导ARF基因座的转录,该机制促进复制蛋白Cdc6的CUL-4A介导的核输出。这些发现的功能意义在于,MUC1(Y60F)诱导的ARF表达进而抑制MDM2会导致p53和同源结构域相互作用蛋白激酶2(HIPK2)丝氨酸/苏氨酸激酶的上调。HIPK2介导的p53第46位丝氨酸的磷酸化进一步与从细胞周期阻滞相关的p21基因表达向凋亡相关的PUMA基因表达的转变相关。我们还表明,MUC1(Y60F)突变体作为肿瘤发生的显性负性抑制剂发挥作用。这些发现表明,MUC1的致癌功能是通过抑制ARF-MDM2-p53途径的激活而赋予的。

相似文献

1
MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.
Cancer Biol Ther. 2008 Dec;7(12):1959-67. doi: 10.4161/cbt.7.12.6956. Epub 2008 Dec 9.
2
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.
EMBO J. 2006 Aug 23;25(16):3774-83. doi: 10.1038/sj.emboj.7601263. Epub 2006 Aug 3.
5
Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):15024-15029. doi: 10.1073/pnas.1611798114. Epub 2016 Dec 12.
6
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.
EMBO J. 2002 Jul 15;21(14):3715-27. doi: 10.1093/emboj/cdf384.
7
Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
Oncogene. 2017 Nov 16;36(46):6391-6407. doi: 10.1038/onc.2017.241. Epub 2017 Jul 24.
9
c-Abl neutralizes the inhibitory effect of Mdm2 on p53.
J Biol Chem. 1999 Mar 26;274(13):8371-4. doi: 10.1074/jbc.274.13.8371.
10
c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF.
Oncogene. 2006 Oct 26;25(50):6666-71. doi: 10.1038/sj.onc.1209671. Epub 2006 May 15.

引用本文的文献

2
Genotoxicity-Stimulated and CYLD-Driven Malignant Transformation.
Cancer Manag Res. 2022 Aug 5;14:2339-2356. doi: 10.2147/CMAR.S373557. eCollection 2022.
3
MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.
Cell Death Dis. 2017 Aug 10;8(8):e2980. doi: 10.1038/cddis.2017.378.
5
MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis.
Cell Death Dis. 2014 Oct 2;5(10):e1438. doi: 10.1038/cddis.2014.421.
6
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Mol Cancer. 2014 May 29;13:129. doi: 10.1186/1476-4598-13-129.
7
Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.
Exp Eye Res. 2013 Dec;117:62-78. doi: 10.1016/j.exer.2013.07.027. Epub 2013 Aug 14.
8
Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.
Tumour Biol. 2013 Dec;34(6):3721-9. doi: 10.1007/s13277-013-0956-z. Epub 2013 Aug 3.
9
Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.
Clin Cancer Res. 2013 Apr 15;19(8):1981-93. doi: 10.1158/1078-0432.CCR-12-2662. Epub 2013 Feb 27.
10
MUC1 drives c-Met-dependent migration and scattering.
Mol Cancer Res. 2012 Dec;10(12):1544-54. doi: 10.1158/1541-7786.MCR-12-0296. Epub 2012 Nov 27.

本文引用的文献

1
MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.
Nat Cell Biol. 2007 Dec;9(12):1419-27. doi: 10.1038/ncb1661. Epub 2007 Nov 25.
2
The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.
Mol Cell. 2007 Sep 21;27(6):992-1004. doi: 10.1016/j.molcel.2007.07.031.
4
Transforming growth factor alpha dependent cancer progression is modulated by Muc1.
Cancer Res. 2007 Jul 15;67(14):6591-8. doi: 10.1158/0008-5472.CAN-06-4518.
6
C. elegans CUL-4 prevents rereplication by promoting the nuclear export of CDC-6 via a CKI-1-dependent pathway.
Curr Biol. 2007 Jun 5;17(11):966-72. doi: 10.1016/j.cub.2007.04.055. Epub 2007 May 17.
7
Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62.
J Biol Chem. 2007 Jul 6;282(27):19321-30. doi: 10.1074/jbc.M703222200. Epub 2007 May 11.
8
MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.
Mol Cell. 2007 Mar 9;25(5):739-50. doi: 10.1016/j.molcel.2007.02.008.
10
Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene.
Cancer Res. 2007 Feb 15;67(4):1853-8. doi: 10.1158/0008-5472.CAN-06-3063.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验